Form 4: Pasithea CEO Tiago Marques Granted Stock Options

Pasithea Therapeutics CEO Tiago Marques received a grant of 493,341 stock options with an exercise price of $0.715, vesting over three years.

Summary

• Tiago Marques, Chief Executive Officer and Director of Pasithea Therapeutics Corp. (KTTA), was granted 493,341 stock options.
• The options have an exercise price of $0.715 per share.
• The transaction date for this grant is listed as October 24, 2025, with an expiration date of October 23, 2035.
• Vesting occurs at a rate of 33% upon the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the subsequent two years, contingent on continuous service to the Issuer.
• Full vesting of the shares underlying the option will occur upon a Change in Control, as defined in the company's 2023 Stock Incentive Plan.
• Vested and exercisable shares underlying the option may be exercised for a period of up to three years following termination of Continuous Service, unless the termination is for Cause.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally a positive sign of management alignment and long-term commitment, though the specific terms and potential dilution warrant consideration. This is a routine compensation disclosure.

Positives

• The granting of stock options aligns management's incentives with shareholder value creation by tying a portion of the CEO's compensation to the company's stock performance.
• The multi-year vesting schedule encourages long-term commitment and retention of the Chief Executive Officer.
• The provision for accelerated vesting upon a Change in Control can incentivize strategic transactions that may benefit shareholders.

Negatives

• The exercise price of $0.715, while standard for option grants, could lead to significant dilution if the stock price appreciates substantially and all options are exercised.
• The transaction date (October 24, 2025) and signature date (October 27, 2025) are in the future, which is unusual for a Form 4 filing that typically reports past transactions.

Risks

• Potential for shareholder dilution if a large number of options are exercised when the stock price is significantly above the exercise price.
• The value of the options is directly tied to the company's stock performance, exposing the CEO's compensation to market volatility and business risks.

Future Outlook

The long-term vesting schedule and expiration date of the options indicate a strategic alignment of the CEO's incentives with the company's sustained performance and growth over the next decade.

Management Comments

• The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended.

Industry Context

Stock option grants are a standard component of executive compensation packages across various industries, particularly in growth-oriented sectors like biotechnology and pharmaceuticals, serving to attract, retain, and motivate key leadership by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• Executive stock option grants are a common practice across industries, particularly in growth-oriented sectors like biotechnology. The specific terms (exercise price, vesting schedule, change in control provisions) are generally within typical ranges for executive compensation, though the exact value and proportion relative to total compensation would require comparison with peer companies of similar size and stage.

Corporate Governance

Related Party Transactions

• The grant of stock options to Tiago Marques, who serves as both the Chief Executive Officer and a Director, constitutes a related party transaction, which is a standard component of executive compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the CEO's incentives drive stock price appreciation; potential for dilution upon the exercise of options.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale and confidence.

Next Steps

• The granted options will begin vesting 33% on the one-year anniversary of the grant date (October 24, 2025).
• The remaining options will vest in equal quarterly installments over the subsequent two years.
• Vested options can be exercised by the grantee for a period of up to three years following termination of Continuous Service, other than a termination for Cause.

Key Dates

Recommendation

This filing reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Pasithea Therapeutics Corp. It aligns management incentives with long-term performance, which is generally positive, but does not provide new operational or financial data to warrant a change in investment stance. Investors should continue to monitor the company's operational performance and broader market conditions.

Keywords

Pasithea Therapeutics, KTTA, Tiago Marques, Stock Options, CEO Compensation, SEC Form 4, Beneficial Ownership, Equity Incentive Plan, Vesting Schedule, Corporate Governance